Compare AEC & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEC | CING |
|---|---|---|
| Founded | 1989 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 70.2M |
| IPO Year | 2011 | 2021 |
| Metric | AEC | CING |
|---|---|---|
| Price | $2.38 | $5.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $21.20 |
| AVG Volume (30 Days) | 40.6K | ★ 252.6K |
| Earning Date | 05-01-2015 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $3.16 |
| 52 Week High | $10.24 | $11.89 |
| Indicator | AEC | CING |
|---|---|---|
| Relative Strength Index (RSI) | 24.12 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $3.18 | N/A |
| Average True Range (ATR) | 0.19 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 7.91 | 0.00 |
Anfield Energy Inc is a mineral exploration and development company. This company focuses on uranium and vanadium development and near-term production. The exploration project of the company includes Shootaring Canyon Mill and Velvet-Wood and Slick Rock Uranium Project from Uranium One and The West Slope Project located in Montrose and San Miguel Counties in southwestern Colorado. The company's geographical segments are Canada and the United States.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.